Biohit Oyj - Decisions of general meeting

Resolutions of the Annual General Meeting of Biohit Oyj

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday 13 April 2011
approved the financial statements of the parent company and the consolidated
financial statements, and discharged the members of the Board of Directors and
the President and CEO from liability for the financial year 2010. 

Distribution of dividends

In accordance with the proposal by the Board of Directors, the AGM decided that
no dividends be paid for the financial year 2010, and that the parent company
loss of EUR 534,475.32 be transferred to the retained profit and loss account. 

Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be
seven (7). Furthermore, the AGM re-elected the following members to the Board
until the end of the next AGM: MSc (Eng.) Kalle Kettunen, Professor Osmo
Suovaniemi, Professor Mikko Salaspuro and MSc (Soc. Sc.) Eero Lehti. CEO
Petteri Kilpinen, MSc (Eng.) Seppo Luode and CFO Saila Miettinen-Lähde were
elected as new members. 

Additionally, the AGM decided that the chairman of the Board of Directors would
be paid a monthly fee of EUR 1,600 and the ordinary members would be paid a
monthly fee of EUR 1,500. 

Auditors

The AGM elected authorised public accountants Ernst & Young Oy as the company's
auditors, with APA Erkka Talvinko as the head auditor, until the end of the
next AGM. 

Authorisation of the Board of Directors to decide on the issue of shares and to
issue special rights entitling the receipt of shares 

The AGM decided to authorise the Board to decide on the issue of shares and to
issue the special rights referred to in Chapter 10, section 1 of the Limited
Liability Companies Act entitling the receipt of shares with the following
terms and conditions: 

The maximum number of new Series B shares to be issued pursuant to the special
rights is 2,000,000, which corresponds to approximately 20% of the company's
Series B shares. 

The authorisation includes the Board of Directors' entitlement to decide on all
terms and conditions regarding the issue of shares and the issue of special
rights. The issue of shares and the issue of special rights entitling to the
receipt of shares can occur deviant from the subscription right of the
shareholders (special issue). The authorisation remains valid for three years
from the resolution of the GM. 


All decisions of the AGM were made unanimously. The minutes of the AGM will be
available for review by shareholders by 15 April 2011 on the company's website
(www.biohit.com/investors) and at the corporate headquarters of Biohit, located
at Laippatie 1, 00880 Helsinki. 



Further information:

Jussi Heiniö, President and CEO
Tel: +358 (0) 9 773 861
jussi.heinio@biohit.com

 Distribution:

NASDAQ OMX Helsinki Oy
Central storage facility (www.oam.fi)
Press
www.biohit.com


About Biohit Oyj:

Biohit Oyj is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. The company follows a goal-directed and long-term innovation
and patenting strategy. 
Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations that can be used to
develop safe and cost-effective liquid handling solutions for laboratory work
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. 

Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips
as well as pipette maintenance and calibration services for research
institutions, healthcare and industrial laboratories. 

The diagnostics business comprises products and analysis systems for the early
diagnosis and prevention of gastrointestinal diseases, such as the blood-sample
based GastroPanel examinations for the diagnosis of stomach illnesses and
associated risks, quick tests for the diagnosis of lactose intolerance and H.
pylori infection in connection with gastroscopy, and the ColonView examination
for the early detection of intestinal bleeding that indicates a risk of
colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in
an anacidic stomach. 

The Biohit Group employs around 420 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA. The company also has a representative office
in Singapore. Biohit's products are also sold through about 200 distributors in
70 countries. 

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group and is traded under the code BIOBV. 

Read more at www.biohit.com